EXACT Sciences Corporation Announces Date For FDA Advisory Committee Meeting

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS) today announced that the U.S. Food and Drug Administration’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is tentatively scheduled to review the premarket approval application (PMA) for the company’s Cologuard stool-DNA-based, non-invasive colorectal cancer screening test on March 26, 2014. The date and details of the meeting are subject to confirmation by the FDA in a Federal Register notice.

Help employers find you! Check out all the jobs and post your resume.